Singapore markets open in 6 hours 55 minutes

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
27.31+1.05 (+4.00%)
At close: 05:38PM CEST
Full screen
Previous close26.26
Bid27.30 x 28400
Ask27.31 x 2100
Day's range26.47 - 27.40
52-week range24.96 - 53.80
Avg. volume3,164,126
Market cap26.83B
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-3.17
Earnings date06 Aug 2024
Forward dividend & yield0.11 (0.42%)
Ex-dividend date29 Apr 2024
1y target est33.40
  • Zacks

    Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study

    Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.

  • Zacks

    ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

    ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.

  • Reuters

    Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia

    A top Bayer pharmaceutical executive said on Wednesday his group will continue slashing managerial jobs this year, planning cuts in Germany, Japan, the United Kingdom, Belgium and the Netherlands as part of the company's internal reorganization. The pharmaceutical unit has already cut around 40% of its managerial positions in the U.S. and has also implemented cuts in Canada, Mexico, Italy, Australia and the Nordic countries, Sebastian Guth, chief operating officer of Bayer Pharmaceuticals, said in an interview with Reuters. Guth would not say exactly how many jobs the company has cut in those countries, but noted that "40% is sort of the range that we tend to see - some are a little lower and some are a little higher."